Bulletin
Investor Alert

Turning Point Therapeutics Inc.

NAS: TPTX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Turning Point Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Aug 16, 2022, 4:47 p.m.

TPTX
/zigman2/quotes/211319679/composite

$

75.99

Change

-0.02 -0.03%

Volume

Volume 359,395

Quotes are delayed by 20 min

/zigman2/quotes/211319679/composite

Today's close

$ 75.49

$ 76.01

Change

+0.52 +0.69%

Day low

Day high

$75.98

$76.01

Open

52 week low

52 week high

$23.77

$82.20

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Turning Point Therapeutics Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue ---25M30.83M
Cost of Goods Sold (COGS) incl. D&A 52,000138,0001.58M-3.97M
COGS excluding D&A -----
Depreciation & Amortization Expense 52,000138,0001.58M2.39M3.97M
Depreciation 52,000138,0001.58M2.39M3.97M
Amortization of Intangibles -----
Gross Income (52,000)(138,000)(1.58M)-26.86M
20172018201920202021 5-year trend
SG&A Expense 16.68M25.5M76.15M151.84M264.86M
Research & Development 15.24M21.06M57.45M112.54M191.77M
Other SG&A 1.44M4.44M18.69M39.31M-
Other Operating Expense -----
Unusual Expense ---32.6M-
EBIT after Unusual Expense ---(161.84M)-
Non Operating Income/Expense -----
Non-Operating Interest Income 136,000856,0005.59M4.54M1.45M
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (16.59M)(24.78M)(72.13M)(157.29M)(236.55M)
Income Tax 1,0001,000---
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (16.59M)(24.79M)(72.13M)(157.29M)(236.55M)
Minority Interest Expense -----
Net Income (16.59M)(24.79M)(72.13M)(157.29M)(236.55M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (16.59M)(24.79M)(72.13M)(157.29M)(236.55M)
Preferred Dividends -----
Net Income Available to Common (16.59M)(24.79M)(72.13M)(157.29M)(236.55M)
EPS (Basic) (0.53)(0.80)(2.99)(3.85)(4.80)
Basic Shares Outstanding 31.04M31.04M24.12M40.84M49.26M
EPS (Diluted) (0.53)(0.80)(2.99)(3.85)(4.80)
Diluted Shares Outstanding 31.04M31.04M24.12M40.84M49.26M
EBITDA (16.68M)(25.5M)(76.15M)(126.84M)(234.03M)
Copyright 2022 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.